These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 24814311)

  • 1. Neoadjuvant endocrine treatment in breast cancer: analysis of daily practice in large cancer center to facilitate decision making.
    Debled M; Auxepaules G; de Lara CT; Garbay D; Brouste V; Bussières E; Mauriac L; MacGrogan G
    Am J Surg; 2014 Nov; 208(5):756-763. PubMed ID: 24814311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
    Freedman OC; Verma S; Clemons MJ
    Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor.
    Markopoulos C
    Surg Oncol; 2008 Aug; 17(2):113-28. PubMed ID: 18178077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant endocrine treatment in primary breast cancer - review of literature.
    Mathew J; Asgeirsson KS; Jackson LR; Cheung KL; Robertson JF
    Breast; 2009 Dec; 18(6):339-44. PubMed ID: 19836953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Utility of neoadjuvant endocrine therapy for breast neoplasms].
    Akashi-Tanaka S
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():559-62. PubMed ID: 17682211
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy.
    Hoff PM; Valero V; Buzdar AU; Singletary SE; Theriault RL; Booser D; Asmar L; Frye D; McNeese MD; Hortobagyi GN
    Cancer; 2000 May; 88(9):2054-60. PubMed ID: 10813717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant use of endocrine therapy in breast cancer.
    Macaskill EJ; Dixon JM
    Breast J; 2007; 13(3):243-50. PubMed ID: 17461898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Utility of Neoadjuvant Endocrine Therapy for Hormone Receptor Positive Breast Cancer.
    Kolberg HC; Aktas B; Liedtke C
    Rev Recent Clin Trials; 2017; 12(2):67-72. PubMed ID: 28155606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Facilitating breast-conserving surgery and preventing recurrence: aromatase inhibitors in the neoadjuvant and adjuvant settings.
    Mamounas EP
    Ann Surg Oncol; 2008 Mar; 15(3):691-703. PubMed ID: 18196346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low risk of recurrence in elderly patients treated with breast conserving therapy in a single institute.
    van der Leij F; van Werkhoven E; Bosma S; Linn SC; Rutgers EJ; van de Vijver MJ; Bartelink H; Elkhuizen PHM; Scholten A
    Breast; 2016 Dec; 30():19-25. PubMed ID: 27587341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?
    van Dam PA; van Dam VC; Altintas S; Papadimitriou K; Rolfo C; Trinh XB
    Eur J Surg Oncol; 2016 Mar; 42(3):333-42. PubMed ID: 26776766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant therapy for breast cancer.
    Zardavas D; Piccart M
    Annu Rev Med; 2015; 66():31-48. PubMed ID: 25386936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
    Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
    Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine therapy in breast cancer: the neoadjuvant, adjuvant, and metastatic approach.
    Reinbolt RE; Mangini N; Hill JL; Levine LB; Dempsey JL; Singaravelu J; Koehler KA; Talley A; Lustberg MB
    Semin Oncol Nurs; 2015 May; 31(2):146-55. PubMed ID: 25951743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neoadjuvant antihormonal treatment of women with breast cancer].
    Tuxen MK; Kamby C; Nielsen DL
    Ugeskr Laeger; 2007 Sep; 169(37):3077-81. PubMed ID: 17877952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant endocrine therapy of breast cancer: a surgical perspective.
    Dixon JM; Anderson TJ; Miller WR
    Eur J Cancer; 2002 Nov; 38(17):2214-21. PubMed ID: 12441257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant endocrine therapy in breast cancer.
    Abrial C; Mouret-Reynier MA; Curé H; Feillel V; Leheurteur M; Lemery S; Le Bouëdec G; Durando X; Dauplat J; Chollet P
    Breast; 2006 Feb; 15(1):9-19. PubMed ID: 16230013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.